Asylia Diagnostics

Foundation date

03/05/2019

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

At Asylia Diagnostics we are building a technology platform that will permit a quick and efficient high-resolution profiling of tumor microenvironment, different immune cells and their subtypes, and cell signaling. With the right data at hand, it will unlock an opportunity to discover novel biomarkers and modes of action for investigational drugs.

Upcoming events

Latest news

  • V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

    16 hours ago

  • Labconsort and NEKTARI join forces for a more sustainable and social industry

    Saturday April 20th 2024

  • BIO INX Complements Advisory Board with Distinguished Industry Leaders

    Thursday April 18th 2024